Enhanced P2X7 activity in human fibroblasts from diabetic patients: A possible pathogenetic mechanism for vascular damage in diabetes

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 7, 2004, Pages 1240-1245

  Solini, Anna ^a   Chiozzi, Paola ^b   Morelli, Anna ^b   Adinolfi, Elena ^b   Rizzo, Roberta ^b   Baricordi, Olavio R ^b   Di Virgilio, Francesco ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

Apoptosis; Atherosclerosis; Cytokines; Diabetes; Fibroblasts; P2 receptors

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE DERIVATIVE; FIBRONECTIN; INTERLEUKIN 6; PURINE P2X7 RECEPTOR; PYRIDOXAL PHOSPHATE 6 AZOPHENYL 2',4' DISULFONIC ACID; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 2',3' DIALDEHYDE ATP; 2',3'-DIALDEHYDE ATP; 3' O (4 BENZOYL)BENZOYLADENOSINE 5' TRIPHOSPHATE; 3'-O-(4-BENZOYL)BENZOYLADENOSINE 5'-TRIPHOSPHATE; ADENOSINE DIPHOSPHATE; APYRASE; CYTIDINE TRIPHOSPHATE; DRUG DERIVATIVE; PURINE P2 RECEPTOR; PYRIDOXAL 5 PHOSPHATE; PYRIDOXAL PHOSPHATE-6-AZOPHENYL-2',4'-DISULFONIC ACID; URIDINE DIPHOSPHATE; URIDINE TRIPHOSPHATE;

APOPTOSIS; ARTICLE; CELL ISOLATION; CELL POPULATION; CELL SECRETION; CELL SHAPE; CELL VACUOLE; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETIC ANGIOPATHY; FIBROBLAST; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; RECEPTOR INTRINSIC ACTIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN BIOPSY; AUTOCRINE EFFECT; BIOSYNTHESIS; CELL MEMBRANE POTENTIAL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PARACRINE SIGNALING; PATHOLOGY; PHYSIOLOGY; SECRETION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; APOPTOSIS; APYRASE; AUTOCRINE COMMUNICATION; CELL SHAPE; CYTIDINE TRIPHOSPHATE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FIBROBLASTS; FIBRONECTINS; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-6; MEMBRANE POTENTIALS; PARACRINE COMMUNICATION; PYRIDOXAL PHOSPHATE; RECEPTORS, PURINERGIC P2; URIDINE DIPHOSPHATE; URIDINE TRIPHOSPHATE;

EID: 3042814728     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000133193.11078.c0     Document Type: Article

References (47)

1. Wilcox JN, Scott NA. Potential role of the adventitia in arteritis and atherosclerosis. Int J Cardiol. 1996;54:S21-S35.
2. Strauss BH, Rabinovitch M. Adventitial fibroblasts: defining a role in vessel wall remodeling. Am J Respir Cell Mol Biol. 2000;22:1-3.
3. Buckley CD, Pilling D, Lord JM, Akbar AN, Scheel-Toellner D, Salmon M. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol. 2001;22:199-204.
4. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodeling. Nat Rev Mol Cell Biol. 2002;3:349-363.
5. Strehlow D, Korn JH. Biology of scleroderma fibroblast. Curr Opin Rheumatol. 1998;10:572-578.
6. Mansbridge JN, Liu K, Pinney RE, Patch R, Ratcliffe A, Naughton GK. Growth factors secreted by fibroblasts: role in healing diabetic foot ulcers. Diabetes Obes Metab. 1999;1:265-279.
7. Sartore S, Chiavegato A, Faggin E, Franch R, Puato M, Ausoni S, Pauletto P. Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant. Circ Res. 2001;89:1111-1121.
8. Wilcox JN, Scott NA. Potential role of the adventitia in arteritis and atherosclerosis. Int J Cardiol. 1996;54:S21-S35.
9. Kolodgie FD, Burke AP, Farb A, Gold HK, Yuan J, Narula J, Finn AV, Virmani R. The thin-cap fibroatheroma: a type of vulnerable plaque, the major precursor lesion to acute coronary syndromes. Curr Opin Cardiol. 2001;16:285-292.
10. Boarder MR, Hourani SM. The regulation of vascular function by P2 receptors: multiple sites and multiple receptors. Trends Pharmacol Sci. 1998;19:99-107.
11. Bunstock G. Purinergic signaling and vascular cell proliferation and death. Arterioscler Thromb Vasc Biol. 2002;22:364-373.
12. You J, Johnson TD, Marrelli SP, Mombouli JV, Bryan RM Jr. P2U receptor-mediated release of endothelium-derived relaxing factor/nitric oxide and endothelium-derived hyperpolarizing factor from cerebrovascular endothelium in rats. Stroke. 1999:30:1125-1133.
13. Boland B, Himpens B, Vincent MF, Gillis JM, Casteels R. ATP activates P2X-contracting and P2Y-relaxing purinoceptors in the smooth muscle of mouse vas deferens. Br J Pharmacol. 1992;107:1152-1158.
14. Griffiths RJ, Stam EJ, Downs JT, Otterness IG, ATP induces the release of IL-1 from LPS-primed cells in vivo. J Immunol. 1995;154:2821-2828.
15. Chaulet H, Desrganges C, Renault MA, Dupuch F, Ezan G, Peiretti F, Loirand G, Pacaud P, Gadeau AP. Extracellular nucleotides induce arterial smooth muscle migration via osteopontin. Circ Res. 2001;89:772-778.
16. Wang DJ, Huang NN, Heppel LA. Extracellular ATP and ADP stimulate proliferation of porcine aortic smooth muscle cells. J Cell Physiol. 1992;153:221-233.
17. Di Virgilio F, Bronte V, Collavo D, Zanovello P. Responses of mouse lymphocytes to extracellular adenosine 5′-triphosphate (ATP). Lymphocytes with cytotoxic activity are resistant to the permeabilizing effects of ATP. J Immunol. 1999;143:1955-1960.
18. Burnstock G, Williams M. P2 purinergic receptors: modulation of cell function and therapeutic potential. J Pharmacol Exp Ther. 2000;295:862-969.
19. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev. 1988;50:413-492.
20. 7 receptor-mediated function in human primary fibroblasts. Diabetologia. 2000;43:1248-1256.
21. Steinberg TH, Silverstein SC. Extracellular ATP4 promotes cation fluxes in the J774 mouse macrophage cell line. J Biol Chem. 1997;262:3118-3122.
22. Steinberg TH, Newman AS, Swanson JA, Silverstein SC. ATP4 permeabilizes the plasma membrane of mouse macrophages to fluorescent dyes. J Biol Chem. 1987;262:8884-8888.
23. Di Virgilio F. The P2Z purinoceptor: an intriguing role in immunità, inflammation and cell death. Immunol Today. 1995;16:524-528.
24. 7). Science. 1996;272:735-738.
25. Ferrari D, Chiozzi P, Falzoni S, Dal Susino M, Melchiorri L, Baricordi OR, Di Virgilio F. Extracellular ATP triggers IL-1β release by activating the purinergic P2Z receptor of human macrophages. J Immunol. 1997; 159:1451-1458.
26. 7 receptors. J Biol Chem. 2001;276:125-132.
27. Falzoni S, Munerati M, Ferrari D, Spisani S, Moretti S, Di Virgilio F. The purinegic receptor of human macrophage cells, Characterization and possible physiological role. J Clin Invest. 1995;95:1207-1216.
28. 7 receptor. Neuropharmacology. 1997;36:1285-1294.
29. 7 receptor coupled to ion fluxes, microvesicle formation and IL-6 release. J Cell Sci. 1999; 112:297-305.
30. 7 receptor. J Physiol. 1999;519:335-346.
31. Rasmussen LM, Heickendorff L. Accumulation of fibronectin in aortas from diabetic patients. A quantitative immunohistochemical and biochemical study. Lab Invest. 1989;61:440-446.
32. Shats EA, Nair CH, Dhall DP. Interaction of endothelial cells and fibroblasts with modified fibrin networks: role in atherosclerosis. Atherosclerosis. 1997;29:9-15.
33. Duner E, Di Virgilio F, Trevisan R, Cipollina MR, Crepaldi G, Nosadini R. Intracellular free calcium abnormalities in fibroblasts from non-insulin-dependent diabetic patients with and without hypertension. Hypertension. 1997;29:1007-1013.
34. Chiquette E, Chilton R. Cardiovascular disease: much more aggressive in patients with type 2 diabetes. Curr Atheroscler Rep. 2002;4:134-142.
35. Lopes-Virella MF, Virella G. Cytokines, modified lipoproteins and arteriosclerosis in diabetes. Diabetes. 1996;45(suppl 3):S40-S44.
36. Loot MA, Kenter SB, Au FL, van Galen WJ, Middelkoop E, Bos JD, Mekkes JR. Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur J Cell Biol. 2002;81:153-160.
37. Twigg SM, Chen MM, Joly AH, Chakrapani SD, Tsubaki J, Kim HS, Oh Y, Rosenfeld RG. Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocrinology. 2001;142:1760-1769.
38. Bodin P, Burnstock G. Increased release of ATP from endothelial cells during inflammation. Inflamm Res. 1998;47:351-354.
39. Mizumoto N, Kumamoto T, Robson SC, Sevigny J, Matsue H, Enjyoji K, Takashima A. CD39 is the dominant Langerhans cell-associated ecto-NTDPase: modulatory roles in inflammation and immune responsiveness. Nat Med. 2002;8:358-365.
40. Burnstock G. Potential therapeutic targets in the rapidly expanding field of purinergic signaling. Clin Med. 2002;2:45-53.
41. Dubyak GR. Focus on "extracellular ATP signaling and P2X nucleotide receptors in monolayers of primary human vascular endothelial cells." Am J Physiol Cell Physiol. 2002;282:C242-C244.
42. 2 or products of activated neutrophils. Am J Med. 1991;91:89S-94S.
43. Di Virgilio F, Solini A. P2 receptors: new potential players in atherosclerosis. Br J Pharmacol. 2002;135:831-842.
44. Andresen JL, Rasmussen LM, Ledet T. Diabetic macroangiopathy and atherosclerosis. Diabetes. 1996;45:S91-S94.
45. 7 receptor channels. J Neurosci. 2002;22:3061-3069.
46. Schneider DB, Vassalli G, Wen S, Driscoll RM, Sassani AB, De Young MB, Linnemann R, Virmani R, Dichek DA. Expression of Fas ligand in arteries of hypercholesterolemic rabbits accelerates atherosclerotic lesion formation. Arterioscl Thromb Vasc Biol. 2000;20:298-308.
47. Guevara NV, Kim HS, Antonova EI, Chan L. The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. Nat Med. 1999;5:335-339.